

Ajanta House, Charkop, Kandivli West, Mumbai 400 067 India T +91 22 6606 1000

- F +91 22 6606 1200
- E info@ajantapharma.com
- W www.ajantapharma.com

4th April, 2016

BSE LIMITED Phiroze Jeejeebhoy Towers Dalal Street, Mumbai - 400 001 National Stock Exchange of India, Exchange Plaza, 5th Floor, Plot no. C/1, G Block, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051

Dear Sir,

Scrip Code: BSE - AJANTPHARM 532331/ NSE - AJANTPHARM EQ

Re: Compliance with Reg. 27(2) of the Listing Regulations - Report on Corporate Governance

Pursuant to Regulation 27(2) of the Listing Regulation, enclosed please find:

- Quarterly Compliance Report on Corporate Governance for the quarter ended on 31st March, 2016.
- 2. Yearly report for the financial year ended 31st March, 2016.

Thanking You,

Yours faithfully, for AJANTA PHARMA LIMITED

GAURANG SHAH Sr. G.M. - Legal & Company Secretary

Encl.: a/a

1. Name of Listed Entity 2. Quarter ending

: Ajanta Pharma Limited : 31st March, 2016

L Composition of Roard of Dir	octors	. <u></u>					
I. Composition of Board of Dir Title Name of the Director (Mr. / Ms)	PAN\$ & DIN	Category (Chairperson /Executive/ Non- Executive/ independent / Nominee) ^{&}	Date of Appointment in the current term /cessation	re	No of Directorship in listed entities including this listed entity (Refer Regulation 25(1) of Listing Regulations)	Number of memberships in Audit/ Stakeholder Committee(s) including this listed entity (Refer Regulation 26(1) of Listing Regulations)	No of post of Chairperson in Audit/ Stakeholder Committee held in listed entities including this listed entity (Refer Regulation 26(1) of Listing Regulations)
		"SAME	AS PREVIOUS Q	UARTER'			· · · · · · · · ·
II. Composition of Committee							······································
Name of Committee		Name of Com	mittee member	5	Category (Chair ent/Nominee)	rperson/Executive/Nor	Executive/Independ
· · · · · · · · · · · · · · · · · · ·		"SAME	AS PREVIOUS Q	UARTER			
III. Meeting of Board of Direc	tors		·		m		
Date(s) of Meeting (if any) in 1		Date(s) of M relevant quar	eeting (if any) ter	in the	Maximum gap t days)	between any two conse	ecutive (in number of
30 th October, 2015	<u> </u>	1 st February, 9 th March, 20	2016		93 (excluding n	neeting days)	
IV. Meeting of Committees	,	· · · · ·		·			
Date(s) of meeting of the relevant quarter	committee in the	Quorum met		the cor previou	of meeting of mmittee in the s quarter	consecutive meeting	
Audit Committee: 1 st February, 2016		Yes, all th members we	e Committee re present	30 th Oct	ober, 2015	93 (excluding meetin	g days)
Stakeholders' Relationship C 1 st February, 2016	ommittee:		nil Kumar, all tee members	30 th Oct	ober, 2015	93 (excluding meetin	g days)

41

 $\dot{\gamma}$

were present	
V. Related Party Transactions	
Subject	Compliance status (Yes/No/NA)refer note below
Whether prior approval of audit committee obtained	Yes
Whether shareholder approval obtained for material RPT	N.A.
Whether details of RPT entered into pursuant to omnibus approval have been reviewed by Audit Committee	Yes

VI. Affirmations

1. The composition of Board of Directors is in terms of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

2. The composition of the following committees is in terms of SEBI(Listing Obligations and Disclosure Requirements) Regulations, 2015

- a. Audit Committee
- b. Nomination & Remuneration committee
- c. Stakeholders relationship committee
- 3. The committee members have been made aware of their powers, role and responsibilities as specified in SEBI (Listing obligations and disclosure requirements) Regulations, 2015.
- 4. The meetings of the Board of Directors and the above committees have been conducted in the manner as specified in SEBI (Listing obligations and disclosure requirements) Regulations, 2015.
- 5. This report will be placed before Board of Directors at the ensuing Board meeting.

Name & Designation : Gaurang C. Shah

Company Secretary / Compliance Officer / Managing Director / CEO : Company Secretary & Compliance Officer

For AJANTA PHARMA LIMITED

GAURANG SHAH Sr. G.M. - Legal & Company Secretary

1. Name of Listed Entity 2. Financial Year ending

3

٠.

: Ajanta Pharma Limited : 31st March, 2016

t Year ending : 31^{ar} March, 201

I. Disclosure on website in terms of Listing Re	gulations		
ltem		Compliance status (Yes/No/NA)refer note below	
Details of business		Yes	
Terms and conditions of appointment of indepe	ndent directors	Yes	
Composition of various committees of board of		Yes	
Code of conduct of board of directors and senio	r management personnel	Yes	
Details of establishment of vigil mechanism/ W		Yes	
Criteria of making payments to non-executive directors		N.A. as disclosure is made in Annual Report	
Policy on dealing with related party transaction	S	Yes	
Policy for determining 'material' subsidiaries	· · · · · · · · · · · · · · · · · · ·	Yes	
Details of familiarization programmes imparted	to independent directors	Yes	
Contact information of the designated officials	of the listed entity who are responsible for	Yes	
assisting and handling investor grievances	r relevent deteile		
E-mail address for grievance redressal and othe Financial results	r relevant details	Yes	
Shareholding pattern	· · · · · · · · · · · · · · · · · · ·	Yes	
	die gemeenies and (their second to	Yes	
Details of agreements entered into with the me New name and the old name of the listed entity	dia companies and/or their associates	N.A.	
Il Annual Affirmations	/	N.A.	
Particulars	Regulation Number		
raruculars	Regulation Number	Compliance status (Yes/No/NA)refer note below	
Independent director(s) have been appointed in terms of specified criteria of 'independence' and/or 'eligibility'	ns of specified criteria of		
Board composition	17(1)	Yes	
Meeting of Board of directors	17(2)	Yes	
Review of Compliance Reports	17(3)	Yes	
Plans for orderly succession for appointments	17(4)	Yes	
Code of Conduct	17(5)	Yes	

Yes	26(2) & 26(5)	Policy with respect to Obligations of directors
Yes	26(4)	Disclosure of Shareholding by Non-Executive
		and Senior management personnel
Yes	26(3)	Affirmation with compliance to code of conduct from members of Board of Directors
Yes	26(1)	Memberships in Committees
Yes	25(7)	Familiarization of independent directors
Yes	25(3) & (4)	Meeting of independent directors
Yes	25(1) & (2)	Maximum Directorship & Tenure
24(5) & (6) - N.A.		with respect to subsidiary of listed entity
24(2),(3) & (4) - Yes	24(2), (3), (4), (5) & (6)	Other Corporate Governance requirements
de India.		material Subsidiary
N.A. as all subsidiaries are incorporated	24(1)	Composition of Board of Directors of unlisted
transactions which need approval.		transactions
N.A. as there are no material related party	23(4)	Approval for material related party
		Committee for all related party transactions
Yes	23(2), (3)	Prior or Omnibus approval of Audit
Yes	23(1),(5),(6),(7) & (8)	Policy for related party Transaction
Yes	22	Vigil Mechanism
it is Not Applicable to Ajanta Pharma Limited.		committee
Dirly Management Committee in the family	21(1) (2) (3) (4)	Committee
Yes	20(1) & (2)	Composition of Stakeholder Relationship
		committee
Yes	19(1) & (2)	Composition of nomination & remuneration
Yes	18(2)	Meeting of Audit Committee
Yes	18(1)	Composition of Audit Committee
		Directors
Yes	17(10)	Performance Evaluation of Independent
Yes	17(9)	Risk Assessment & Management
Yes	17(8)	Compliance Certificate
Yes	17(7)	Minimum Information
Yes	17(6)	Fees/compensation

Note

1 In the column "Compliance Status", compliance or non-compliance may be indicated by Yes/No/N.A. For example, if the Board has been composed in accordance with the requirements of Listing Regulations, "Yes" may be indicated. Similarly, in case the Listed Entity has no related party transactions, the words "N.A." may be indicated.

2 If status is "No" details of non-compliance may be given here.

3 If the Listed Entity would like to provide any other information the same may be indicated here.

III Affirmations:

The Listed Entity has approved Material Subsidiary Policy and the Corporate Governance requirements with respect to subsidiary of Listed Entity have been complied.

Name & Designation : Gaurang C Shah

Company Secretary / Compliance Officer / Managing Director / CEO : Company Secretary & Compliance Officer

For AJANTA PHARMA LIMITED

GAURANG SHAH Sr. G.M. - Legal & Company Secretary